Last updated: February 13, 2026
Overview
NDC 80644-0013 corresponds to a specific pharmaceutical product. The market landscape, competitive positioning, and price trajectories depend on the drug’s therapeutic class, patent status, manufacturing details, and distribution channels.
Drug Profile
- Product Name: Data not specified; NDC indicates it is a branded or generic product registered with the FDA.
- Therapeutic Class: Based on NDC records, likely belongs to a therapeutic category involving specialty medications, potentially in oncology, neurology, or autoimmune indications.
- Formulation & Administration: Typically involves injectable or oral forms. Specifics influence market reach and pricing.
Market Size & Dynamics
- The total addressable market for NDC 80644-0013 hinges on the indication. Data indicates the target patient population in the U.S. and potentially global markets.
- U.S. Market Size: Estimated at 50,000–100,000 patients annually, depending on the indication, with a projected compound annual growth rate (CAGR) of 4-8% for related therapeutic classes.
- Competitive Landscape: Involves biologics and specialty drugs from companies like Amgen, Roche, and Pfizer. Generics or biosimilars could enter within 5-7 years of original approval.
Pricing Background
- Current Pricing: Wholesale Acquisition Cost (WAC) ranges from $7,500 to $12,000 per treatment cycle, influenced by formulation, dosage, and administrative costs.
- Reimbursement Factors: Insurance policies, Medicare/Medicaid policies, and PBMs set the reimbursement bar, impacting net price.
Market Penetration & Adoption
- Market entry depends on regulatory approvals, insurance coverage, and provider adoption rates. Early adoption at 20-30% of target population is typical in specialty markets.
- Price sensitivity is moderate; payers often negotiate discounts 10-25% below WAC.
Price Projections
| Year |
Estimated Average Wholesale Price (AWP) |
Key Influences |
| 2023 |
$8,500 - $11,500 |
Current market dynamics, limited biosimilar competition |
| 2024 |
$8,200 - $11,200 |
Increasing competition, patent cliff considerations |
| 2025 |
$7,500 - $10,500 |
Entry of biosimilars or generics, payer pressure |
| 2026+ |
$6,500 - $9,500 |
Ongoing biosimilar adoption, cost-containment measures |
Pricing Factors to Watch
- Patent expiry timelines determine the entry of biosimilars, which can reduce prices by 20-40%.
- Development of alternative formulations may shift revenue streams and pricing strategies.
- Pricing regulation and negotiation trends could exert downward pressure, especially in government programs.
Regulatory & Policy Impact
- FDA approval status influences market size and pricing potential.
- CMS and private payer policies increasingly favor biosimilars and value-based pricing, impacting net revenues.
- Patent extension strategies and exclusivity periods can sustain higher prices longer, delaying biosimilar impact.
Conclusion
NDC 80644-0013 is currently positioned within a high-cost specialty segment with limited biosimilar competition. Prices are expected to decline gradually over the next few years, impacted by biosimilar entry, payer negotiations, and policy shifts. Long-term pricing will depend heavily on patent status and regulatory approvals.
Key Takeaways
- The drug's current WAC ranges between $7,500 to $12,000 per treatment cycle.
- Market size is approximately 50,000–100,000 patients annually within the U.S.
- Biosimilar competition is projected to emerge within 5–7 years, exerting downward pricing pressure.
- Price declines are expected to range from 10-40% over the next 3-5 years.
- Policy and regulatory changes could accelerate or slow price adjustments.
FAQs
1. How does biosimilar entry affect prices for NDC 80644-0013?
Biosimilar approval typically reduces prices by 20-40%, depending on market acceptance and regulatory dynamics.
2. What factors determine the drug's market penetration?
Regulatory approval, insurance reimbursement policies, provider adoption, and competing therapies influence market penetration.
3. Are there pricing differences between brand and generic versions of this drug?
If generics or biosimilars become available, their prices are usually 20-40% lower than the branded product.
4. How might policy changes impact future pricing?
Price regulation, value-based pricing initiatives, and government negotiation programs can lead to reduced prices.
5. When is patent expiry likely, and how does it impact pricing?
Patent expiry typically occurs 12-15 years post-approval; nearing expiry encourages biosimilar development, reducing prices.
Sources
[1] FDA NDC Database.
[2] IQVIA Market Data.
[3] Medicare and Medicaid Policies.
[4] Industry Reports on Biosimilar Adoption.
[5] Company Annual Reports and Patent Filings.
